A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy

• DOI: 10.1016/j.vaccine.2004.03.014
• Publication Date: 2004-04-10T11:53:41Z
• Authors: G.P Talwar; Komal Raina; Jagdish C Gupta; Ruma Ray; S Wadhwa; Mushir M Ali
• Keywords: Immunogen; Toxoid

Previous studies with a semi-synthetic vaccine indicated the utility of immunization against luteinising-hormone-releasing-hormone (LHRH) in prostate cancers. To overcome the limitations of the previous vaccine, which caused carrier induced suppression of antibody response on repeated immunizations and was costly to synthesize, two recombinant vaccines were designed, in which diptheria or tetanus toxoid used as carriers were replaced by 4-5 T non B peptides. The paper reports the immunogenecity, efficacy and safety of these multimer vaccines in rats, a homologous experimental animal. All animals generated anti-LHRH antibodies, which caused the decline of testosterone to castration levels at and above 0.15 OD units of antibody titres. The prostate was significantly atrophied in all animals immunized with these vaccines.